AYTU Aytu BioPharma, Inc.
Healthcare$2.18-0.46%ClosedMarket Cap: $17.7M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.66
P/S
0.31
EV/EBITDA
-0.53
DCF Value
$-20.36
FCF Yield
9.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
62.5%
Operating Margin
-26.8%
Net Margin
-60.2%
ROE
-148.9%
ROA
-30.5%
ROIC
-23.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 null | $12.4M | 55.1% | $-4.1M | $-5.6M | $— | — |
| Q2 null | $15.2M | 60.0% | $-2.0M | $-10.6M | $— | — |
| Q1 null | $13.9M | 66.1% | $-1.5M | $2.0M | $— | — |
| Q4 null | $15.1M | 67.8% | $-7.6M | $-19.8M | $— | — |
| FY null | $66.4M | 69.0% | $-7.8M | $-13.6M | $— | — |
| Q3 null | $18.5M | 69.4% | $2.4M | $4.0M | $— | — |
| Q2 null | $16.2M | 66.5% | $-1.7M | $788.0K | $— | — |
| Q1 null | $16.6M | 72.3% | $-930.0K | $1.5M | $— | — |
| Q4 null | $18.0M | 66.2% | $-3.6M | $-4.6M | $— | — |
| FY null | $65.2M | 75.3% | $-1.6M | $-15.8M | $— | — |
| Q3 null | $14.0M | 73.9% | $-1.6M | $-2.9M | $— | — |
| Q2 2024 | $18.7M | 77.9% | $3.1M | $-220.0K | $-0.04 | — |